Biontech Se Stock Analysis

BNTX Stock  USD 104.76  6.00  6.08%   
BioNTech SE is undervalued with Real Value of 113.76 and Target Price of 141.79. The main objective of BioNTech stock analysis is to determine its intrinsic value, which is an estimate of what BioNTech SE is worth, separate from its market price. There are two main types of BioNTech's stock analysis: fundamental analysis and technical analysis.
The BioNTech stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. BioNTech is usually not traded on Thanksgiving Day, Christmas Day, New Year 's Day, National Mourning Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day, Labour Day. BioNTech Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

BioNTech Stock Analysis Notes

About 63.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.08. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioNTech SE has Price/Earnings To Growth (PEG) ratio of 0.04. The entity recorded a loss per share of 3.13. The firm last dividend was issued on the 2nd of June 2022. BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. Biontech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3082 people. For more info on BioNTech SE please contact Ugur MD at 49 6131 9084 or go to https://www.biontech.de.

BioNTech Quarterly Total Revenue

1.19 Billion

BioNTech SE Investment Alerts

BioNTech SE generated a negative expected return over the last 90 days
BioNTech SE has high historical volatility and very poor performance
The company reported the previous year's revenue of 2.75 B. Net Loss for the year was (677.7 M) with profit before overhead, payroll, taxes, and interest of 2.21 B.
About 63.0% of the company shares are held by company insiders
Latest headline from zacks.com: Heres Why Summit Therapeutics Stock Soared 15 percent on Friday

BioNTech SE Upcoming and Recent Events

Earnings reports are used by BioNTech to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period..
25th of March 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
25th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

BioNTech Largest EPS Surprises

Earnings surprises can significantly impact BioNTech's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2020-05-12
2020-03-31-0.27-0.240.0311 
2019-11-14
2019-09-30-0.16-0.130.0318 
2020-03-31
2019-12-31-0.17-0.26-0.0952 
View All Earnings Estimates

BioNTech Environmental, Social, and Governance (ESG) Scores

BioNTech's ESG score is a quantitative measure that evaluates BioNTech's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of BioNTech's operations that may have significant financial implications and affect BioNTech's stock price as well as guide investors towards more socially responsible investments.

BioNTech Thematic Classifications

In addition to having BioNTech stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech Idea
Biotech
Biotechnology and pharmaceuticals production and services
Computers Idea
Computers
USA Equities from Computers industry as classified by Fama & French
IT Idea
IT
Information technology and IT services

BioNTech Stock Institutional Investors

Shares
Capital International Inc /ca/2024-12-31
668.3 K
Altrinsic Global Advisors Llc2024-12-31
627.5 K
Bnp Paribas Arbitrage, Sa2024-12-31
614.3 K
Ubs Group Ag2024-12-31
529.1 K
Dz Bank Ag Deutsche Zentral-genossenschaftsbank Frankfurt Am Main2024-12-31
501.9 K
Dekabank Deutsche Girozentrale2024-12-31
481.4 K
Fred Alger Management, Llc2024-12-31
465.4 K
Aberdeen Group Plc2024-12-31
385.7 K
Squarepoint Ops Llc2024-12-31
369.6 K
Baillie Gifford & Co Limited.2024-12-31
8.2 M
Fmr Inc2024-12-31
7.7 M
Note, although BioNTech's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

BioNTech Market Capitalization

The company currently falls under 'Large-Cap' category with a current market capitalization of 23.74 B.

BioNTech Profitablity

The company has Profit Margin (PM) of (0.24) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of 0.13 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.13.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.03)(0.03)
Return On Capital Employed(0.07)(0.06)
Return On Assets(0.03)(0.03)
Return On Equity(0.03)(0.03)

Management Efficiency

BioNTech SE has return on total asset (ROA) of (0.0353) % which means that it has lost $0.0353 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0336) %, meaning that it created substantial loss on money invested by shareholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to -0.03 in 2025. Return On Capital Employed is likely to rise to -0.06 in 2025. At this time, BioNTech's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 14.1 B in 2025, whereas Other Current Assets are likely to drop slightly above 143.6 M in 2025.
Last ReportedProjected for Next Year
Book Value Per Share 80.75  84.78 
Tangible Book Value Per Share 75.87  79.67 
Enterprise Value Over EBITDA(45.28)(47.55)
Price Book Value Ratio 1.35  1.41 
Enterprise Value Multiple(45.28)(47.55)
Price Fair Value 1.35  1.41 
Enterprise ValueBB
Understanding the operational decisions made by BioNTech management offers insights into its financial robustness. This evaluation is crucial for assessing the stock's investment potential.
Operating Margin
0.1332
Profit Margin
(0.24)
Beta
1.08
Return On Assets
(0.04)
Return On Equity
(0.03)

Technical Drivers

As of the 22nd of April, BioNTech shows the Risk Adjusted Performance of (0.06), mean deviation of 2.6, and Standard Deviation of 3.3. BioNTech SE technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.

BioNTech SE Price Movement Analysis

The output start index for this execution was thirty-nine with a total number of output elements of twenty-two. BioNTech SE Triple Exponential Moving Average indicator shows smoothing effect of BioNTech price series composite of a single exponential moving average, a double exponential moving average and a triple exponential moving average.

BioNTech Outstanding Bonds

BioNTech issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. BioNTech SE uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most BioNTech bonds can be classified according to their maturity, which is the date when BioNTech SE has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

BioNTech Predictive Daily Indicators

BioNTech intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioNTech stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

BioNTech Corporate Filings

6K
4th of April 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
2nd of April 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
10th of March 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
4th of March 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
3rd of February 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
14th of January 2025
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
27th of December 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify
6K
13th of December 2024
A report filed by foreign private issuers with SEC. A foreign private issuer is a non-U.S. company with securities traded on U.S. exchanges.
ViewVerify

BioNTech Forecast Models

BioNTech's time-series forecasting models are one of many BioNTech's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioNTech's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About BioNTech Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how BioNTech prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioNTech shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BioNTech. By using and applying BioNTech Stock analysis, traders can create a robust methodology for identifying BioNTech entry and exit points for their positions.
Last ReportedProjected for Next Year
Pretax Profit Margin(0.25)(0.26)
Operating Profit Margin(0.48)(0.45)
Net Loss(0.24)(0.25)
Gross Profit Margin 0.80  0.84 

Current BioNTech Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. BioNTech analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. BioNTech analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
141.79Strong Buy21Odds
BioNTech SE current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most BioNTech analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand BioNTech stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of BioNTech SE, talking to its executives and customers, or listening to BioNTech conference calls.
BioNTech Analyst Advice Details

BioNTech Stock Analysis Indicators

BioNTech SE stock analysis indicators help investors evaluate how BioNTech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading BioNTech shares will generate the highest return on investment. By understating and applying BioNTech stock analysis, traders can identify BioNTech position entry and exit signals to maximize returns.
Begin Period Cash Flow11.7 B
Long Term Debt214.7 M
Common Stock Shares Outstanding240.4 M
Total Stockholder Equity19.4 B
Tax Provision-12.4 M
Quarterly Earnings Growth Y O Y-0.432
Property Plant And Equipment Net1.2 B
Cash And Short Term Investments16.8 B
Cash9.8 B
Accounts Payable426.7 M
Net Debt-9.5 B
50 Day M A104.1451
Total Current Liabilities2.5 B
Other Operating Expenses4.1 B
Non Current Assets Total3.7 B
Forward Price Earnings7.0373
Non Currrent Assets Other36.1 M
Stock Based Compensation100.9 M

Additional Tools for BioNTech Stock Analysis

When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.